Last reviewed · How we verify

NCT04822480

Evaluation of a Telehealth DPP With Medicare Patients at the University of Mississippi Medical Center

Active, enrolled Last updated 29 April 2024
What this trial tests

trial testing Diabetes Prevention Program (DPP) in PreDiabetes in 500 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
1 February 2020
Primary endpoint
31 December 2023
31 December 2024

Quick facts

Lead sponsorUniversity of Mississippi Medical Center
StatusActive, enrolled
Study typeOBSERVATIONAL
Enrollment500
Start date1 February 2020
Primary completion31 December 2023
Estimated completion31 December 2024
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Mississippi Medical Center

Who can join

18 and older, any sex, with PreDiabetes or Prediabetic State. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The National Diabetes Prevention Program (DPP) is an evidence-based, 12-month lifestyle change program to prevent or delay the onset of type 2 diabetes mellitus (herein referred to as 'diabetes') among adults with prediabetes. The Department of Preventive Medicine, University of Mississippi Medical Center (UMMC), in partnership with the American Medical Association, is collaborating to develop and implement the DPP as a clinical service for UMMC patients beginning in September 2020. We aim to recruit 245 patients per year over 3 years. Because this is the first attempt to develop and implement the DPP as a clinical service at the UMMC, we are proposing to conduct a comprehensive process, outcome, impact and return on investment evaluation. An effectiveness-implementation hybrid research design will be used to (1) evaluate a multifaceted implementation strategy and the effectiveness and impact of the DPP delivered using telehealth by UMMC's Department of Preventive Medicine; (2) conduct an analysis on medical expenditures among those who participate in a DPP to measure net savings and return on investment (ROI) relative to non-participants; (3) conduct a longitudinal cohort analysis to assess incidence of diabetes and changes in body composition, biomarkers, and psycho-social behavioral constructs among those who participate in a DPP relative to those who do not. The findings from this comprehensive research evaluation will be used to (1) improve clinical operations and implementation; (2) demonstrate the cost benefit of the DPP as a clinical service for patients with diabetes risk; and (3) provide empirical support for delivering the DPP via different modalities including telehealth to reduce risk and improve health outcomes among patients.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Telehealth Diabetes Prevention Program for Adults With Prediabetes in an Academic Medical Center Setting: Protocol for a Hybrid Type III Trial.
    Gamble A, Khan T, Hughes A, Guo Y, et al · · 2023 · PMID 37955955 · DOI 10.2196/50183

Verify or expand the search:

Other trials of Diabetes Prevention Program (DPP)

Trials testing the same drug.

Other recruiting trials for PreDiabetes

Currently open trials in the same condition.

Other University of Mississippi Medical Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04822480.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing